Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

66.10USD
4:01pm EDT
Change (% chg)

$0.48 (+0.73%)
Prev Close
$65.62
Open
$65.44
Day's High
$66.27
Day's Low
$65.41
Volume
1,674,976
Avg. Vol
2,257,529
52-wk High
$68.12
52-wk Low
$55.10

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $104,570.50
Shares Outstanding(Mil.): 1,593.58
Dividend: 0.64
Yield (%): 3.90

Financials

  ABBV.N Industry Sector
P/E (TTM): 17.98 29.17 29.94
EPS (TTM): 3.65 -- --
ROI: 12.09 13.48 13.01
ROE: 138.75 14.39 14.16

BRIEF-Abbvie CEO Richard Gonzalez's FY 2016 total compensation was $21 mln

* CEO Richard Gonzalez's FY 2016 total compensation was $21.0 million versus $20.8 million in FY 2015 - sec filing

Mar 20 2017

BRIEF-Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir

* Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c

Mar 14 2017

BRIEF-Abbvie CEO Richard Gonzalez's total 2016 compensation was $21 mln vs. $20.8 mln in 2015

* CEO Richard Gonzalez's total 2016 compensation was $21 million versus $20.8 million in 2015 - sec filing

Mar 08 2017

BRIEF-Abbvie's CEO total 2016 compensation was $21 mln - SEC filing

* CFO William Chase's 2016 total compensation was $8.8 million versus $7.6 million in 2015

Mar 08 2017

TG Therapeutics' leukemia drug clears key study, shares pop

TG Therapeutics Inc said a combination of its experimental cancer drug, ublituximab, and approved treatment Imbruvica was found to be more effective in high-risk leukemia patients, compared with Imbruvica as a standalone therapy.

Mar 06 2017

UPDATE 3-TG Therapeutics' leukemia drug clears key study, shares pop

* Shares rise as much as nearly 117 pct to $11.60 (Adds details, updates shares)

Mar 06 2017

BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B

* Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

Feb 27 2017

BRIEF-Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax

* Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

Feb 27 2017

Fitch Affirms Astrazeneca at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, February 22 (Fitch) Fitch Rating has affirmed UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating at 'A'. The Outlook is Stable. The rating remains underpinned by AZ's leading position in the global pharmaceutical sector, supported by a business risk profile characterised by scale, diversification, and focus on innovation. The group is accelerating the dev

Feb 22 2017

BRIEF-Abbvie announces $5 bln increase to stock repurchase program

* Abbvie announces $5 billion increase to stock repurchase program Source text for Eikon: Further company coverage:

Feb 17 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.80 +0.32
Pfizer Inc. (PFE.N) $34.18 +0.18
Novartis AG (NOVN.S) CHF73.85 +0.10
Merck & Co., Inc. (MRK.N) $63.19 +0.01
Roche Holding Ltd. (ROG.S) CHF252.90 0.00
Roche Holding Ltd. (RO.S) CHF252.75 +0.25
Abbott Laboratories (ABT.N) $44.70 -0.03
Eli Lilly and Co (LLY.N) $84.24 +0.06
Sanofi SA (SASY.PA) €83.47 +0.60

Earnings vs. Estimates